Other GH secretagogues / GHRPs
Muscle & Strength · GH secretagogue / ghrelin receptor agonist
Tier D+
Bottom line
Read Off Label grades Other GH secretagogues / GHRPs as D+ (3.9/10) based on weak evidence, low-med benefit magnitude, and a med-risk safety profile.
WADA coverage: growth hormone secretagogues/GHS, anamorelin, capromorelin, macimorelin, tabimorelin, GH-releasing peptides/GHRPs, alexamorelin, examorelin/hexarelin, GHRP-1, GHRP-3, GHRP-4 and GHRP-5.
Studied, labeled, or reported-use context: No approved enhancement dose; diagnostic/clinical dosing varies by agent — Some approved for narrow indications/diagnostics; many research chemicals; WADA S2 prohibited; not individualized guidance.
What the evidence says
WADA coverage: growth hormone secretagogues/GHS, anamorelin, capromorelin, macimorelin, tabimorelin, GH-releasing peptides/GHRPs, alexamorelin, examorelin/hexarelin, GHRP-1, GHRP-3, GHRP-4 and GHRP-5. Existing rows cover MK-677, ipamorelin and GHRP-2/GHRP-6. Additional WADA alias coverage: CJC-1293.
Mechanism
Ghrelin-receptor agonists and GHRPs stimulate pulsatile GH release; gray-market use aims at recovery, sleep, appetite, fat loss and lean-mass effects.
Studied, labeled, or reported dose & route
No approved enhancement dose; diagnostic/clinical dosing varies by agent
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Other GH secretagogues / GHRPs's effects?
- Read Off Label rates the evidence for Other GH secretagogues / GHRPs as Weak and the benefit magnitude as low-med, producing an overall grade of D+ (3.9/10). WADA coverage: growth hormone secretagogues/GHS, anamorelin, capromorelin, macimorelin, tabimorelin, GH-releasing peptides/GHRPs, alexamorelin, examorelin/hexarelin, GHRP-1, GHRP-3, GHRP-4 and GHRP-5.
- What safety findings are reported for Other GH secretagogues / GHRPs?
- Other GH secretagogues / GHRPs has a med risk profile in the database. Med (appetite changes, edema, glucose effects, cortisol/prolactin effects for some peptides, product-quality risk) Legal status: Some approved for narrow indications/diagnostics; many research chemicals; WADA S2 prohibited.
- What doses or routes are reported for Other GH secretagogues / GHRPs?
- No approved enhancement dose; diagnostic/clinical dosing varies by agent This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Other GH secretagogues / GHRPs work?
- Ghrelin-receptor agonists and GHRPs stimulate pulsatile GH release; gray-market use aims at recovery, sleep, appetite, fat loss and lean-mass effects.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.